Pardes Biosciences, Inc.
(NASDAQ GM: PRDS)
Rigrodsky Law, P.A. is investigating Pardes Biosciences, Inc. (“Pardes”) regarding possible breaches of fiduciary duties and other violations of law related to Pardes’ agreement to be acquired by MediPacific. Under the terms of the agreement, Pardes shareholders will receive no less than $2.02 per share in cash.